Quick Answer
Indivior Pharmaceuticals, Inc. reported Operating Income Loss of $262.00 million for the year ending 2025.
- Indivior Pharmaceuticals, Inc. showed an increase of +589.5% in Operating Income Loss from 2024 to 2025.
- This data is from Indivior Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $75.00 million | Q2 2024: -$118.00 million | Q3 2024: $35.00 million | Q4 2024: $46.00 million | Q1 2025: $66.00 million | Q2 2025: $72.00 million | Q3 2025: $43.00 million.
- Over the full 4 years of available data (2022 to 2025), Indivior Pharmaceuticals, Inc.'s Operating Income Loss has grown by 423.5%.
- Historical annual values: Fiscal year 2025: $262.00 million | Fiscal year 2024: $38.00 million | Fiscal year 2023: -$152.00 million | Fiscal year 2022: -$81.00 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: